CureVac (NASDAQ: CVAC) stock is up after the business announced the appointment of Dr. Malte Greune as COO and the transition of Dr. Florian von der Mulbe to head the RNA printer’s expedited development.
Dr. Greune comes to the organization from Sanofi-Aventis Deutschland, where he worked in a variety of management roles. He was the Vice President and General Manager of the Cartridges, Devices, and Insulin Technology Group.
CureVac N.V., a clinical-stage biopharmaceutical business, is working on a number of transformational treatments based on messenger ribonucleic acid (mRNA).
CureVac’s stock was trading at $75.55 at the time of writing, up 12 percent. A 52-week low of $36.15 and a 52-week high of $151.80 are the stock’s low and high respectively.
2021 (C) Benzinga.com. Benzinga does not offer financial advice. All intellectual property rights are reserved./n
